First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment

Tuberculosis is known to be the biggest global health problem, causing the most deaths by a single infectious agent. Vaccine-development efforts are extremely important. This paper represents the results of the first-in-human trial of recombinant subunit tuberculosis vaccine GamTBvac in a Phase I st...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasina, Daria V., Kleymenov, Denis A., Manuylov, Victor A., Mazunina, Elena P., Koptev, Egor Yu., Tukhovskaya, Elena A., Murashev, Arkady N., Gintsburg, Alexander L., Gushchin, Vladimir A., Tkachuk, Artem P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963980/
https://www.ncbi.nlm.nih.gov/pubmed/31683812
http://dx.doi.org/10.3390/vaccines7040166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963980/
https://www.ncbi.nlm.nih.gov/pubmed/31683812
http://dx.doi.org/10.3390/vaccines7040166

Ejemplares similares